GV.PA stock trades €0.0018 on EURONEXT 10 Feb 2026: heavy volume signals short-term interest

GV.PA stock is the most active small-cap on EURONEXT intraday, trading at €0.0018 with a 5.88% rise and 38,489,238 shares exchanged so far. The surge lifts volume to 2.71x average, a notable liquidity spike for Genomic Vision SA (GV.PA). Traders are reacting to low float dynamics, continued negative EPS of -0.11, and very low market cap €693,191. We review intraday drivers, fundamentals, valuation and a model-based 12‑month forecast to frame risk and potential upside for Europe-listed Genomic Vision SA.

Intraday price and volume snapshot for GV.PA stock

GV.PA stock opened at €0.0018, with a day low of €0.0015 and a day high of €0.0020. Current price is €0.0018, up 5.88% from the previous close of €0.0017. Volume stands at 38,489,238 versus an average volume of 14,217,513, giving a relative volume of 2.71. The 50‑day average price is €0.004844 and the 200‑day average is €0.013997, both well above today’s level and signalling a long downtrend.

Why GV.PA stock is one of the most active names today

High trade count reflects low share price and speculative flows rather than a change in core fundamentals. Genomic Vision SA (GV.PA) has 385,105,984 shares outstanding and tiny market capitalisation €693,191, which makes even modest orders move the price significantly. Intraday spikes often follow liquidity runs, news reprints, or portfolio rebalancing among microcap traders. Sector context: Healthcare on Europe markets is mixed; the group’s diagnostics niche remains high innovation but high risk.

Fundamentals and valuation: GV.PA analysis

Genomic Vision reports negative earnings with EPS -0.11 and a negative PE ratio. Key ratios show price to sales 0.47 and enterprise value to sales 1.60. Cash per share is €0.00557 while free cash flow per share is negative. Current ratio 0.91 suggests limited short‑term liquidity cushion. Research and development to revenue is high at 2.08x, reflecting R&D intensity. These metrics indicate structural losses and thin liquidity, consistent with a microcap turnaround risk profile.

Technical picture and trading metrics for GV.PA stock

Technicals show strong downward bias: price sits below both the 50‑day and 200‑day averages, with year high €0.094 and year low €0.0014. Short‑term momentum is episodic; today’s jump to €0.0020 intraday reversed toward the close. Volume surge and a relative volume of 2.71 point to trader-driven moves. For active traders, watch support near €0.0014 and resistance around €0.0048 (50‑day average). Volatility and low liquidity increase execution risk.

Meyka AI grade, sector view and GV.PA price targets

Meyka AI rates GV.PA with a score out of 100: 62.62 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. It reflects microcap risk, weak profitability, and some asset value. Realistic price targets: a 12‑month base case target €0.0040, conservative downside €0.0009, and upside scenario €0.0100. Those targets reflect liquidity risk and binary outcomes typical in diagnostics small caps.

Risks and catalysts shaping GV.PA outlook

Primary risks: continued negative earnings, fragile balance sheet, and low free cash flow. The company’s strategic alliances provide catalyst potential—collaborations with Quest Diagnostics and Institut Pasteur could generate validation events or commercial deals. Regulatory or R&D progress would be a clear positive. Given current metrics, small operational wins can produce outsized price moves, while funding needs or dilution remain the main downside triggers.

Final Thoughts

Key takeaways: GV.PA stock is trading at €0.0018 on EURONEXT with heavy intraday volume and a 5.88% uptick, driven by microcap liquidity and short‑term trading interest. Fundamentals remain weak: EPS -0.11, negative free cash flow and a small market cap €693,191. Meyka AI’s forecast model projects a 12‑month base case target of €0.0040, implying an upside of 122.22% versus the current price €0.0018; forecasts are model‑based projections and not guarantees. Our analysis frames GV.PA as a high‑volatility spec trade: potential reward exists if partnerships or R&D milestones convert to revenue, but funding needs and dilution risk are material. For active traders on EURONEXT, position sizing and strict stop management are essential. For longer‑term investors, monitor cash runway, any financing announcements, and verification of product commercialisation steps. For more real‑time data and model updates see our Meyka AI stock page GV.PA on Meyka. Additional company details available at the issuer site Genomic Vision and market listings Reuters company page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.